Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Spesolimab in Korean Patients With Flares With Generalized Pustular Psoriasis

NCT06886009 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06886009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06886009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Spesolimab in Korean Patients With Flares With Generalized Pustular Psoriasis
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Withdrawn
Start date
March 31, 2026
Completion date
June 8, 2029
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

generalized pustular psoriasis